🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jennifer Kherani

ORCID: 0009-0003-0198-4443
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Papers

Driven by 7 papers — median percentile 0. Top paper: “Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial”.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800
N/A
3.5DataRank · unranked
140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications(2022)10.1038/s41467-022-28848-x
N/A
3.4DataRank · unranked
117 citations

Helen Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong +27 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004
N/A
2.5DataRank · unranked
57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278
N/A
0.724DataRank · unranked
124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754
N/A
0.406DataRank · unranked
14 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1
N/A
0DataRank · unranked
0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more